There are currently 103 clinical trials in Lubbock, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Tech University Health Sciences Center, Covenant Children's Hospital, Joe Arrington Cancer Research and Treatment Center and UMC Cancer Center / UMC Health System. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
TRIAD Appendicitis Decision-making Surveys
NCT05887414
Recruiting
While appendectomy has been the main treatment of appendicitis for over 100 years, recent European studies found that, at least among highly selected patients, antibiotics alone can be an effective alternative. Surgeons and patients alike have a difficult time deciding if surgery or antibiotics are the best choice to treat appendicitis. The goal of the TRIAD is to evaluate the patients who are a part of the TRIAD implementation program and assess satisfaction and decisional regret for patients w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2023
Locations: Texas Tech University, Lubbock, Texas
Conditions: Appendicitis
Register for Updates
Tocotrienols for Obesity of Postmenopausal Women
NCT03705845
Recruiting
Postmenopausal women are at a risk of excessive weight gain, bone loss, hypertension, and metabolic syndrome. Obesity-induced chronic low-grade inflammation is initiated by excess nutrients in metabolic cells. Recent studies have indicated tocotrienols (one kind of vitamin E, a potent antioxidant) supplement may be good for mitigating negative impacts of obesity in postmenopausal women. The purpose of the study is to examine the effect of 24-week tocotrienols on obesity-associated outcome measur... Read More
Gender:
Female
Ages:
All
Trial Updated:
04/10/2023
Locations: Texas Tech University Health Sciences Center, Lubbock, Texas
Conditions: Obesity, Postmenopausal Women
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: Joe Arrington Cancer Research, Lubbock, Texas
Conditions: Lung Cancer
Register for Updates
Annatto-derived GG for Statin-associated Myopathy
NCT05312424
Recruiting
To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.
Gender:
All
Ages:
40 years and above
Trial Updated:
12/07/2022
Locations: Texas Tech University Health Sciences Center, Lubbock, Texas
Conditions: Myopathy; Primary
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Southwest Cancer Treatment & Research Center, Lubbock, Texas
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Reducing Mental Health in Informal Caregivers
NCT05334992
Recruiting
The overarching goal of this project is to evaluate if evidence-based interventions can reduce PDG, burden, and stress in informal caregivers of individuals with dementia
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/11/2022
Locations: Texas Tech University, Lubbock, Texas
Conditions: Mental Health Issue, Grief, Burden, Caregiver
Register for Updates
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
NCT02013336
Recruiting
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
Gender:
All
Ages:
Between 12 months and 20 years
Trial Updated:
03/17/2022
Locations: Texas Tech University Health Sciences Center, Lubbock, Texas
Conditions: Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
Register for Updates